Get the Stockscreener App
0.2772
2.08%
-0.0059
Curanex Pharmaceuticals Inc stock is traded at $0.2772, with a volume of 76,962.
It is down -2.08% in the last 24 hours and down -24.59% over the past month.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
See More
Previous Close:
$0.2831
Open:
$0.2713
24h Volume:
76,962
Relative Volume:
0.36
Market Cap:
$7.86M
Revenue:
-
Net Income/Loss:
$-435.00K
P/E Ratio:
-17.66
EPS:
-0.0157
Net Cash Flow:
$-665.30K
1W Performance:
+3.43%
1M Performance:
-24.59%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.2713
$0.2952
1-Week Range:
$0.262
$0.3099
52-Week Range:
$0.262
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Name
Curanex Pharmaceuticals Inc
Sector
Industry
Phone
718-673-6078
Address
2 JERICHO PLAZA,, JERICHO
Compare CURX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.2772 | 8.02M | 0 | -435.00K | -665.30K | -0.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Curanex Pharmaceuticals Inc Stock (CURX) Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Comparing Curanex Pharmaceuticals (CURX) & The Competition - Defense World
Curanex Pharmaceuticals Inc (CURX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Curanex Pharmaceuticals (CURX) versus Its Peers Financial Survey - Defense World
Financial Contrast: Curanex Pharmaceuticals (CURX) & Its Peers - Defense World
Curanex Pharmaceuticals appoints new chief financial officer - MSN
Contrasting Curanex Pharmaceuticals (CURX) and The Competition - Defense World
Curanex Pharmaceuticals appoints Wanjun Zhang as CFO following resignation By Investing.com - Investing.com Nigeria
Curanex Pharmaceuticals appoints Wanjun Zhang as CFO following resignation - Investing.com
Curanex Pharmaceuticals (CURX) Competitors and Alternatives 2026 - MarketBeat
Curanex Pharmaceuticals Appoints New Chief Financial Officer - TipRanks
Curanex Pharmaceuticals Announces CFO Transition - TradingView — Track All Markets
Curanex Pharmaceuticals Inc Announces Executive Changes - marketscreener.com
Curanex Pharmaceuticals announces pricing of its initial public offering - MSN
Curanex Pharmaceuticals Inc(NasdaqCM: CURX) added to S&P TMI Index - MarketScreener
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Weekly Research Analysts’ Ratings Updates for Curanex Pharmaceuticals (CURX) - Defense World
Curanex Pharmaceuticals Inc (CURX) is looking forward to a strong quarter - setenews.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Get insights into the top gainers and losers of Wednesday's pre-market session. - Chartmill
Curanex Pharmaceuticals Faces Nasdaq Delisting Warning - MSN
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Wall Street Zen Downgrades Curanex Pharmaceuticals (NASDAQ:CURX) to Sell - Defense World
Curanex Pharmaceuticals Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
Curanex Pharmaceuticals Inc SEC 10-Q Report - TradingView
Curanex Pharmaceuticals receives Nasdaq notice on minimum bid price requirement - Investing.com Australia
Curanex Pharmaceuticals Inc Stock (CURX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):